A
Alfica Sehgal
Researcher at Alnylam Pharmaceuticals
Publications - 59
Citations - 3534
Alfica Sehgal is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Gene & Small interfering RNA. The author has an hindex of 17, co-authored 57 publications receiving 2841 citations. Previous affiliations of Alfica Sehgal include Genzyme.
Papers
More filters
Journal ArticleDOI
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
Hyukjin Lee,Abigail K. R. Lytton-Jean,Yi Chen,Kevin T. Love,Angela I. Park,Emmanouil D. Karagiannis,Alfica Sehgal,William Querbes,Christopher Zurenko,Muthusamy Jayaraman,Chang G. Peng,Klaus Charisse,Anna Borodovsky,Muthiah Manoharan,Jessica S. Donahoe,Jessica Truelove,Matthias Nahrendorf,Robert Langer,Daniel G. Anderson +18 more
TL;DR: In this paper, a tetrahedral DNA strand self-assembles into tetrahedron nanoparticles that can deliver small interfering RNA molecules to cells and suppress genes in tumours.
Journal ArticleDOI
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Teresa Coelho,David H. Adams,Ana Martins da Silva,Pierre Lozeron,Philip N. Hawkins,Timothy Mant,Javier Perez,Joseph Chiesa,Steve Warrington,Elizabeth Tranter,Malathy Munisamy,Rick Falzone,Jamie Harrop,Jeffrey Cehelsky,Brian Bettencourt,Mary Geissler,James Butler,Alfica Sehgal,Rachel Meyers,Qingmin Chen,Todd Borland,Renta Hutabarat,Valerie A. Clausen,Rene Alvarez,Kevin Fitzgerald,Christina Gamba-Vitalo,Saraswathy V. Nochur,Akshay Vaishnaw,Dinah W.Y. Sah,Jared Gollob,Ole B. Suhr +30 more
TL;DR: A therapeutic approach mediated by RNA interference (RNAi) could reduce the production of transthyretin in peripheral nerves and the heart as mentioned in this paper, which is caused by the deposition of hepatocyte-derived tranthymretin amyloid in peripheral nerve and heart.
Journal ArticleDOI
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
Alfica Sehgal,Scott A Barros,Lacramioara Ivanciu,Brian C. Cooley,June Qin,Tim Racie,Julia Hettinger,Mary Carioto,Yongfeng Jiang,Josh Brodsky,Harsha K. Prabhala,Xuemei Zhang,Husain Attarwala,Renta Hutabarat,Don Foster,Stuart Milstein,Klaus Charisse,Satya Kuchimanchi,Martin Maier,Lubo Nechev,Pachamuthu Kandasamy,Alexander V Kel'in,Jayaprakash K. Nair,Kallanthottathil G. Rajeev,Muthiah Manoharan,Rachel Meyers,Benny Sørensen,Amy Simon,Yesim Dargaud,Claude Negrier,Rodney M. Camire,Akin Akinc +31 more
TL;DR: Treatment with ALN-AT3 promoted hemostasis in mouse models of hemophilia and led to improved thrombin generation in an NHP model of hemophile A with anti-factor VIII inhibitors.
Journal ArticleDOI
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
Donald Foster,Christopher R. Brown,Sarfraz Shaikh,Casey Trapp,Mark K Schlegel,Kun Qian,Alfica Sehgal,Kallanthottathil G. Rajeev,Vasant Jadhav,Muthiah Manoharan,Satya Kuchimanchi,Martin Maier,Stuart Milstein +12 more
TL;DR: Liver exposure data indicate that the improvement in potency is predominantly due to increased metabolic stability of the siRNA conjugates, and this work employed an iterative screening approach across multiple siRNAs to arrive at advanced designs with low 2′-deoxy-2′-fluoro content that yield significantly improved potency and duration in preclinical species, including non-human primate.
Journal ArticleDOI
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates.
Jayaprakash K. Nair,Husain Attarwala,Alfica Sehgal,Qianfan Wang,Krishna Aluri,Xuemei Zhang,Minggeng Gao,Ju Liu,Ramesh Indrakanti,Sally Schofield,Philip Kretschmer,Christopher R. Brown,Swati Gupta,Jennifer L. S. Willoughby,Julie A. Boshar,Vasant Jadhav,Klaus Charisse,Tracy Zimmermann,Kevin Fitzgerald,Muthiah Manoharan,Kallanthottathil G. Rajeev,Akin Akinc,Renta Hutabarat,Martin Maier +23 more
TL;DR: Compared two siRNAs of the same sequence but with different modification pattern resulting in different degrees of protection against nuclease activity enhanced stability translated into substantially improved liver exposure, gene silencing efficacy and duration of effect in mice.